Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer

Summary

To determine if erlotinib given orally along with concurrent whole brain irradiation in lung cancer patients with brain metastases improves median overall survival and enhances local control compared to those treated with WBRT alone, without significantly increasing the risk of side effects or lowering quality of life.

Timeline

Start

2012-05

Primary completion

2017-12-10

Completion

2018-12-10

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

Indications